Ocular Therapeutix is pivoting aggressively toward its AXPAXLI retina program, with R&D spending nearly tripling to $54.1M in 2026Q2 and driving operating losses to -$82.1M. However, the commercial foundation is weakening as DEXTENZA revenue declined 18.7% yea...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | -$0.35+11.5% vs -$0.40 | $13M+2.1% vs $13M |
Q2 2026 May 5, 2026 | -$0.41-28.1% vs -$0.32 | $11M-15.2% vs $13M |
Q1 2026 Feb 5, 2026 | -$0.29+12.1% vs -$0.33 | $13M-17.8% vs $16M |
Q4 2025 Nov 4, 2025 | -$0.37+5.1% vs -$0.39 | $15M-9.9% vs $16M |
Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel described as alignment with the Food and Drug Administration on the company's planned submission package for wet age-related macular degeneration, or wet AMD.
BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that have received multiple AXPAXLI injections in support of the Company's application for repeat dosing Commercial readiness accelerates ahead of potential 2027 launch as AXPAXLI is well positioned to potentially be the first TKI approved for wet AMD BEDFORD, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the successful completion of its Pre-New Drug Application (NDA) Meeting with the U.S. Food and Drug Administration (FDA) for its investigational product candidate AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).
BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.
Benchmark OCUL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ocular Therapeutix, Inc. (OCUL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.00 | $2.19B | -7.04 | -18.67% | -513.17% | -54.85% | — | |
| $3.02 | $329.76M | -1.50 | — | — | -5.76% | — | |
| $0.56 | $10.83M | -0.17 | — | — | -187.45% | — | |
| $1.35 | $81.43M | -2.41 | — | — | -53.14% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $8.50 | $462.48M | -11.49 | -3.13% | -35.69% | -50.64% | — |
Ocular Therapeutix, Inc. (OCUL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ocular Therapeutix, Inc. (OCUL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jun 12, 2026·SEC
May 5, 2026·SEC
Get notified when OCUL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ocular Therapeutix, Inc. (OCUL) stock FAQ — growth, dividends, profitability & financials explained
Ocular Therapeutix, Inc. (OCUL) reported $52.1M in revenue for fiscal year 2025. This represents a 520440% increase from $0.0M in 2012.
Ocular Therapeutix, Inc. (OCUL) saw revenue decline by 18.7% over the past year.
Ocular Therapeutix, Inc. (OCUL) reported a net loss of $301.4M for fiscal year 2025.
Ocular Therapeutix, Inc. (OCUL) has a return on equity (ROE) of -54.9%. Negative ROE indicates the company is unprofitable.
Ocular Therapeutix, Inc. (OCUL) had negative free cash flow of $255.1M in fiscal year 2025, likely due to heavy capital investments.
